<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03255993</url>
  </required_header>
  <id_info>
    <org_study_id>SPH3127-102</org_study_id>
    <nct_id>NCT03255993</nct_id>
  </id_info>
  <brief_title>The Tolerability and Pharmacokinetics of Multiple Doses of SPH3127 in Chinese Healthy People</brief_title>
  <official_title>Multiple Doses Study to Evaluate the Tolerability and Pharmacokinetics of SPH3127 in Chinese Healthy People</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Pharmaceuticals Holding Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Pharmaceuticals Holding Co., Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was a single center, parallel, randomized, double blind, placebo-controlled phase
      Ib clinical trial to to evaluate the safety and tolerability and pharmacokinetics of SPH3127
      tablet in healthy subjects by increasing multiple dosing
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Three panels(100mg, 200mg, 400mg), each consisting of eight participants (The number of
      individual subjects in each group was not less than 1/3 of the total number).Participants
      begin to receive the first dose of SPH3127 100mg. Then Participants begin to receive the
      second dose of SPH3127 200mg,after the researchers confirmed that the 100mg dose group was
      safe and well tolerated.Then the third dose of SPH3127 400mg must wait for the result of the
      second dose's safety and tolerability. If the subjects during escalating dose to the biggest
      tolerate dose group were not well tolerated, the study must adjust the maximum dose group and
      fall to a low dose group to conduct another test.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 23, 2017</start_date>
  <completion_date type="Anticipated">September 20, 2018</completion_date>
  <primary_completion_date type="Anticipated">September 20, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events (AEs)</measure>
    <time_frame>Baseline to 13-16 days post last dose</time_frame>
    <description>to assess incidence and intensity of Adverse Events according to Common Toxicity Criteria (CTC version 4.03) associated with increasing doses of SPH3127</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma area under curve (AUC)(0-∞) of SPH3127</measure>
    <time_frame>10 minutes predose, 0.17hour, 0.33hour, 0.5hour, 0.75hour, 1hour, 1.25hour, 1.5hour, 2hour, 4hour, 6hour, 8hour, 12hour postdose at Day 1 and 7; 10 minutes predose at Day 2; 10 minutes predose, 1hour postdose at Day 5 or 6</time_frame>
    <description>to evaluate Plasma AUC(0-∞) of SPH3127</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in laboratory hematology values</measure>
    <time_frame>Baseline to 13-16 days post last dose</time_frame>
    <description>to evaluate the Change from baseline in laboratory hematology values</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in laboratory chemistry values</measure>
    <time_frame>Baseline to 13-16 days post last dose</time_frame>
    <description>to evaluate the Change from baseline in laboratory chemistry values</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in laboratory urinalysis values</measure>
    <time_frame>Baseline to 13-16 days post last dose</time_frame>
    <description>to evaluate the Change from baseline in laboratory urinalysis values</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in ECG</measure>
    <time_frame>Baseline to 13-16 days post last dose</time_frame>
    <description>to evaluate the Change from baseline in ECG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of SPH3127</measure>
    <time_frame>10 minutes predose, 0.17hour, 0.33hour, 0.5hour, 0.75hour, 1hour, 1.25hour, 1.5hour, 2hour, 4hour, 6hour, 8hour, 12hour postdose at Day 1 and 7;10 minutes predose at Day 2; 10 minutes predose, 1hour postdose at Day 5 or 6</time_frame>
    <description>to evaluate Plasma Cmax of SPH3127</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Maximum time to peak (Tmax) of SPH3127</measure>
    <time_frame>10 minutes predose, 0.17hour, 0.33hour, 0.5hour, 0.75hour, 1hour, 1.25hour, 1.5hour, 2hour, 4hour, 6hour, 8hour, 12hour postdose at Day 1 and 7;10 minutes predose at Day 2; 10 minutes predose, 1hour postdose at Day 5 or 6</time_frame>
    <description>to evaluate Plasma Tmax of SPH3127</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent terminal half-life of SPH3127</measure>
    <time_frame>10 minutes predose, 0.17hour, 0.33hour, 0.5hour, 0.75hour, 1hour, 1.25hour, 1.5hour, 2hour, 4hour, 6hour, 8hour, 12hour postdose at Day 1 and 7;10 minutes predose at Day 2; 10 minutes predose, 1hour postdose at Day 5 or 6</time_frame>
    <description>to evaluate terminal half-life of SPH3127</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>SPH3127 100mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of SPH3127 50 mg*2 qd *7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo to SPH3127 100mg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A single dose of placebo matching to SPH3127 50mg*2 qd *7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SPH3127 200mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of SPH3127 100 mg*2 qd *7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo to SPH3127 200mg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A single dose of placebo matching to SPH3127 100mg*2 qd *7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SPH3127 400mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of SPH3127 100 mg*4 qd *7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo to SPH3127 400mg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A single dose of placebo matching to SPH3127 100mg*4 qd *7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SPH3127 50mg</intervention_name>
    <description>SPH3127 50mg</description>
    <arm_group_label>SPH3127 100mg</arm_group_label>
    <other_name>SPH3127 is a new study drug for hypertension</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SPH3127 100mg</intervention_name>
    <description>SPH3127 100mg</description>
    <arm_group_label>SPH3127 200mg</arm_group_label>
    <arm_group_label>SPH3127 400mg</arm_group_label>
    <other_name>SPH3127 is a new study drug for hypertension</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo matching to SPH3127 50mg</intervention_name>
    <description>Placebo matching to SPH3127 50mg</description>
    <arm_group_label>Placebo to SPH3127 100mg</arm_group_label>
    <other_name>Placebo is oral tablet to matching to SPH3127 50mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo matching to SPH3127 100mg</intervention_name>
    <description>Placebo matching to SPH3127 100mg</description>
    <arm_group_label>Placebo to SPH3127 200mg</arm_group_label>
    <arm_group_label>Placebo to SPH3127 400mg</arm_group_label>
    <other_name>Placebo is oral tablet to matching to SPH3127 50mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The body mass index is 18-28kg/m2 (including the critical value), which allows the
             minimum weight of men to be 50kg (including the critical value) and 45kg for women
             (including the critical value).

          2. Before the study,participant has know about the significance , potential benefits,
             inconveniences and potential risks of the study

          3. Participant has understood the research's procedure and sign the informed consent .

        Exclusion Criteria:

          -  Participant who are Pregnancy, lactating women, and planned trials begin within six
             months of pregnancy

          -  Participant who has abnormal Physical examination, laboratory examination results and
             clinical significance (such as: liver function examination - aspartate
             aminotransferase (AST) and alanine aminotransferase (ALT) more than 1.5 times that of
             the upper limit of normal)

          -  Participant who has a history of cardiovascular, liver, kidney, digestive tract,
             nervous system, blood system, familial hematologic disease, abnormal thyroid function,
             or mental abnormality

          -  Participant who has drug allergy history and anaphylactic reaction

          -  Participant who took oral contraceptive in 6 months

          -  Participant who used any drug (including Chinese herbal medicine) within 1 week.

          -  Participant who donated blood within 2 months

          -  Participant who participated clinical trials of any drug in 3 months (as subjects)

          -  Participant who has any positive result of virus serology check: human
             immunodeficiency virus antigen antibody (HIV Ag/Ab) and hepatitis c virus (HCV) -
             immunoglobulin G(IgG) antibody to IgG, hepatitis b surface antigen (HBsAg) and
             treponema pallidum antibody (TP)

          -  Participant who are used to smoke, alcohol abuse, eat coffee and strong tea and drug
             abuse

          -  Participant who the researchers believe that there are volunteers who are not suitable
             for the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>wenhong m xia, doctor</last_name>
    <phone>61871700</phone>
    <phone_ext>8131</phone_ext>
    <email>xiawh@sphchina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The capital medical university affiliated Beijing anzhen hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>YANG LIN</last_name>
      <email>linyang3623@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 8, 2017</study_first_submitted>
  <study_first_submitted_qc>August 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 21, 2017</study_first_posted>
  <last_update_submitted>October 27, 2017</last_update_submitted>
  <last_update_submitted_qc>October 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

